Insulin, Neurogenetics and Memory in Alzheimer's Disease
Sponsor
US Department of Veterans Affairs (U.S. Fed)
Overall Status
Completed
CT.gov ID
NCT00018382
Collaborator
(none)
1
41
Study Details
Study Description
Brief Summary
This study examines the use of insulin-sensitizing compounds, as therapeutic agents for cognitive impairment in Alzheimer's disease.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Study Design
Study Type:
Interventional
Allocation:
Randomized
Masking:
Double
Primary Purpose:
Treatment
Official Title:
Insulin, Neurogenetics and Memory in Alzheimer's Disease: A Novel Therapeutic Approach
Study Start Date
:
Oct 1, 1999
Study Completion Date
:
Mar 1, 2003
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
55 Years
to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Men and women with mild Alzheimer's Disease without serious medical or psychiatric comorbid conditions.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | VA Puget Sound Health Care System | Seattle | Washington | United States | 98108 |
Sponsors and Collaborators
- US Department of Veterans Affairs
Investigators
- : Steven Kahn, M.D.,
- : Sanjay Asthana, M.D.,
- : Alfred Fujimoto, M.D.,
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00018382
Other Study ID Numbers:
- AGCG-012-98S
First Posted:
Jul 5, 2001
Last Update Posted:
Jan 21, 2009
Last Verified:
Dec 1, 2004